1-[2,3-Difluoro-6-(tritylamino)phenyl]-2,2,2-trifluoroethanone | 205756-70-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-[2,3-Difluoro-6-(tritylamino)phenyl]-2,2,2-trifluoroethanone
• CAS: 205756-70-3
• 化学式: C₂₇H₁₈F₅NO
• 分子量: 467.438
• InChiKey: RLJMCVYDQXVYDX-UHFFFAOYSA-N

物化性质

• 沸点：
  509.6±50.0 °C(predicted)
• 密度：
  1.324±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-[2,3-Difluoro-6-(tritylamino)phenyl]-2,2,2-trifluoroethanone 在 盐酸 、 lithium aluminium tetrahydride 、 正丁基锂 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 16.75h， 生成 (E)-2-(6-Amino-2,3-difluoro-phenyl)-4-cyclopropyl-1,1,1-trifluoro-but-3-en-2-ol
  参考文献：
  名称：

  4,1-Benzoxazepinone analogues of efavirenz (Sustiva™) as HIV-1 reverse transcriptase inhibitors

  摘要：

  A series of 4,1-benzoxazepinone analogues of efavirenz (Sustiva(TM)) as potent NNRTIs has been discovered. The cis-3-alkylbenzoxazepinones are more potent then the trans isomers and can be synthesized preferentially by a novel stereoselective cyclization. The best compounds are potent orally bioavailable inhibitors of both wild-type HIV-1 and its clinically relevant K103N mutant virus, but are highly protein-bound in human plasma. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00239-6
• 作为产物：
  描述：

  3,4-二氟苯胺 在 盐酸 、 正丁基锂 、 TEA 、 对甲苯磺酸 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 二氯甲烷 、 甲苯 为溶剂， 反应 9.5h， 生成 1-[2,3-Difluoro-6-(tritylamino)phenyl]-2,2,2-trifluoroethanone
  参考文献：
  名称：

  Synthesis and evaluation of analogs of Efavirenz (SUSTIVATM) as HIV-1 reverse transcriptase inhibitors

  摘要：

  Efavirenz (SUSTIVA(TM)) is a potent non-nucleoside reverse transcriptase inhibitor. Due to the observation of breakthrough mutations of the reverse transcriptase enzyme during Efavirenz therapy, we sought to develop an optimized second generation series. To that end, SAR of the substituents on the aromatic ring was undertaken and the results are summarized here. The 5,6-difluoro (4f) and the 6-methoxy (4m) substituted benzoxazinones were determined to be equipotent, and as a result such substitution patterns will be incorporated in second generation scaffolds. (C) 1999 DuPont Pharmaceuticals. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00486-2

文献信息

• 4,4-disubstituted-1, 4-dihydro-2H-3, 1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and intermediates and processes for making the same
  申请人：——

  公开号：US20020040138A1

  公开（公告）日：2002-04-04

  The present invention relates to benzoxazinones of formula I: 1 or stereoisomeric forms or mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, methods of using the same for treating viral infection or as an assay standard or reagent, and intermediates and processes for making the same.

  本发明涉及公式I的苯并噁唑酮：1或其立体异构体或混合物，或其药学上可接受的盐形式，其用作HIV反转录酶的抑制剂，以及包含其的制药组合物和诊断试剂盒，使用其的治疗病毒感染的方法或用作检测标准或试剂，以及制造其的中间体和过程。
• 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP1359147A1

  公开（公告）日：2003-11-05

  The present invention relates to benzoxazinones of formula I, or stereoisomeric forms or mixtures, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of HIV reverse transcriptase, and to pharmaceutical compositions and diagnostic kits comprising the same, methods of using same for treating viral infection or as an assay standard or reagent, and intermediates and processes for making the same.

  本发明涉及式 I 的苯并恶嗪酮类化合物、 或立体异构体形式或混合物，或其药学上可接受的盐形式，它们可用作 HIV 逆转录酶的抑制剂，还涉及包含这些物质的药物组合物和诊断试剂盒、使用这些物质治疗病毒感染或用作检测标准或试剂的方法，以及制造这些物质的中间体和工艺。
• 4,4-DISUBSTITUTED-1,4-DIHYDRO-2H-3,1-BENZOXAZIN-2-ONES USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS AND INTERMEDIATES AND PROCESSES FOR MAKING THE SAME
  申请人：Bristol-Myers Squibb Pharma Company

  公开号：EP0929533B1

  公开（公告）日：2003-09-03
• US6140499A
  申请人：——

  公开号：US6140499A

  公开（公告）日：2000-10-31
• US6303780B1
  申请人：——

  公开号：US6303780B1

  公开（公告）日：2001-10-16